Anti-CHD1L (Chromodomain-helicase-DNA-binding Protein 1-like, Amplified in Liver Cancer Protein 1, A

CHD-1L is a 98-118kD member of the SNF2/RAD54 helicase family of proteins. It is expressed in hepatocytes, possesses ATPase activity, and likely promotes chromatin remodeling at sites of DNA damage. It also is considered an oncogene. CHD-1L upregulates ARHGEF9 trabscription, an action that promotes Cdc42 activity with accompanying filopodia formation and EMT. It also binds apoptosis-mediating Nur77, blocking its migration from nucleus-to-mitochondria. Human CHD-1L is 897aa in length. It contains a helicase ATP-binding domain aa58-223, a C-terminal helicase domain aa351-513, a coiled-coil region aa38-675 and one Macro domain that binds poly-ADP-ribose and targets DNA damage sites aa704-897. There are at least two Ser/Thr phosphorylation sites. There are multiple potential splice variants. One isoform contains an alternative start site at Met114, a second isoform possesses a deletion of aa43-246, a third isoform shows a three aa substitution for aa363-897, and a fourth isoform combines a 16aa insertion after 386aa with a five aa substitution for aa425-897. Over aa759-879, human CHD-1L shares 94% aa identity with mouse CHD-1L. Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 1ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.